JPH0223952A - Thrombolic body - Google Patents
Thrombolic bodyInfo
- Publication number
- JPH0223952A JPH0223952A JP63175549A JP17554988A JPH0223952A JP H0223952 A JPH0223952 A JP H0223952A JP 63175549 A JP63175549 A JP 63175549A JP 17554988 A JP17554988 A JP 17554988A JP H0223952 A JPH0223952 A JP H0223952A
- Authority
- JP
- Japan
- Prior art keywords
- projections
- base
- blood flow
- embolus
- embolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005189 Embolism Diseases 0.000 claims description 37
- 230000003073 embolic effect Effects 0.000 claims description 29
- 230000017531 blood circulation Effects 0.000 abstract description 27
- 210000004204 blood vessel Anatomy 0.000 abstract description 20
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 208000007536 Thrombosis Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000010102 embolization Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000010108 arterial embolization Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000026426 spleen abscess Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Landscapes
- Surgical Instruments (AREA)
Abstract
Description
【発明の詳細な説明】
〔発明の目的〕
（産業上の利用分野）
本発明は、医療分野において、動脈の閉塞に用いる塞栓
体に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Object of the Invention] (Industrial Application Field) The present invention relates to an embolic body used for occluding arteries in the medical field.
（従来の技術）
軽カテーテル動脈塞栓術（■ｒａｎｓｃａｔｈｅｔｅｒ
Ａｒｔｅｒｉａｌ Ｅｍｂｏｌｉｚａｔｉｏｎ 以下
、ＴＡＢと呼ぶ。）は、悪性腫瘍、血管性病変、牌機能
六進−症、出血等に対゛して、治療効果を得る目的で、
それらの病巣に関与している動脈に、カテーテルを用い
て塞栓物質を注入し、動脈を閉塞させるものである。(Conventional technology) Light catheter arterial embolization (■ranscatheter
Arterial Embolization Hereinafter referred to as TAB. ) is used for the purpose of obtaining therapeutic effects against malignant tumors, vascular lesions, hexagonism, bleeding, etc.
A catheter is used to inject an embolic substance into the arteries involved in these lesions to occlude the arteries.
塞栓に用いる塞栓物質には、融解や吸収により注入後数
時間から数日間で再開通する短期塞栓物質や数週間以上
経てから再開通する長期塞栓物質、さらに、再開通しな
い永久塞栓物質があり、主要なものとして、ゼラチンス
ポンジ（非抗原性のゼラチンを重合させたもので、１１
ｍ〜２１ａ角の細片または数百μの粉末にして用いる。Embolic substances used for embolization include short-term embolic substances that recanalize within a few hours to several days after injection due to melting or absorption, long-term embolic substances that recanalize after several weeks, and permanent embolic substances that do not recanalize. The main type is gelatin sponge (polymerized non-antigenic gelatin, with 11
It is used in the form of small pieces of square meters to 21 square meters or powder of several hundred micrometers.
）、リビオドール（ヨード化によりＸＩ！不透過にした
ケシ油）、スチールコイル（ステンレススチールのコイ
ルに多数の糸状物を着けたもの）があり、この他に、イ
バロン（ポリビニルアルコール、固体）シアノアクリレ
ート（瞬間接着剤）、エタノール、自己凝血塊、シリコ
ンゴム小球がある。), Libiodol (poppy oil made XI! opaque by iodination), Steel Coil (stainless steel coil with many threads attached), and Ibalon (polyvinyl alcohol, solid) cyanoacrylate. (instant adhesive), ethanol, autoclotted blood, and silicone rubber globules.
そして、牌機能六道症に対するＴＡＥは、牌臓の一部に
梗塞を作り、牌臓の容積を減少させることにより、血小
板数を増加させることと、牌血流量を減少させ門脈圧を
下げることを目的とし、一般に、１ｊＩｌ〜２ｍｇ＋角
のゼラチンスポンジの細片が使われ、この他に、粉末（
ゼルフォームパウダ）スチールコイル、イバロン、エタ
ノールを使用したという報告もある。TAE for splenic dysfunction involves creating an infarction in a part of the spleen and decreasing the splenic volume, thereby increasing the number of platelets, decreasing the splenic blood flow, and lowering portal venous pressure. For this purpose, 1 to 2 mg square pieces of gelatin sponge are generally used;
There are also reports of using steel coil (Zelfoam powder), Ibalon, and ethanol.
これらの塞栓物質を使用して、牌臓に対するＴＡＥを行
なうと、塞栓物質が注入された動脈枝の血流が急速に減
少し、注入直後５分〜６分以内に血流が無くなるため、
強い疼痛、発熱、牌膿瘍、敗血症等の合併症が現われる
。When performing TAE on the spleen using these embolic substances, the blood flow in the arterial branch into which the embolic substances were injected rapidly decreases, and the blood flow disappears within 5 to 6 minutes immediately after injection.
Complications such as severe pain, fever, spleen abscess, and sepsis appear.
また、悪性腫瘍に対するＴＡＥは、ｔ４瘍の栄養血管つ
まり栄養を供給する動脈を閉塞して、腫瘍を壊死させる
ことを目的とし、一般に、１ｊｗ〜２ａｍ角のゼラチン
スポンジの細片、リビオドールが使われ、これに、抗癌
剤を併用するが、この場合にも、注入直後に血流が無く
なるため、疼痛、発熱等の合併症が現われる。In addition, TAE for malignant tumors aims to cause necrosis of the tumor by occluding the feeding vessels of the T4 tumor, that is, arteries that supply nutrients, and Libiodol, a strip of gelatin sponge measuring 1 cm to 2 cm square, is generally used. This is combined with an anticancer drug, but in this case as well, complications such as pain and fever occur because blood flow disappears immediately after injection.
（発明が解決しようとする課題）
上述したように、従来の塞栓物質は、いずれも、注入直
後に、血流が無くなるため、急速な１向、梗塞により、
疼痛等の合併症が現われる。(Problems to be Solved by the Invention) As mentioned above, with all conventional embolic substances, blood flow disappears immediately after injection, resulting in rapid infarction.
Complications such as pain appear.
本発明は、このような点に鑑み成されたもので、注入直
後の血流を確保し、少しずつ時間をかけて血流を減少さ
せる塞栓体を提供しようとするものである。The present invention has been made in view of these points, and aims to provide an embolus that secures blood flow immediately after injection and gradually reduces blood flow over time.
（課題を解決するための手段）
本発明の塞栓体１．１１は、基部２．１２の周囲に複数
の突部３，１３を放射状に突設し、それぞれの突部３，
１３の間に流通間隙４．１４を形成して成り、上記基部
２．１２はそれぞれの突部３，１３についてその突設さ
れた方向を維持する強腹を有することを特徴とするもの
であり、請求項２のように、複数の突部３を同一平面上
に配置して基部２から突設してもよく、また、請求項３
のように、複数の突部１３を基部１２から立体的に突設
してもよいが、請求項４のように、全体の投影面積を基
部２．１２の中心から突部３，１３の先端までの長さを
半径とする円の面積の３０％〜６０％とすることが望ま
しい。(Means for Solving the Problem) The embolus body 1.11 of the present invention has a plurality of protrusions 3, 13 radially protruding around the base 2.12, and each protrusion 3,
A flow gap 4.14 is formed between the protrusions 3 and 13. , as in claim 2, the plurality of protrusions 3 may be arranged on the same plane and protrude from the base 2;
As shown in FIG. It is desirable that the radius be 30% to 60% of the area of a circle whose radius is the length up to.
（作用）
本発明の塞栓体１．１１は、流通間隙４．１４により、
塞栓術直後の血流が確保され、基部２．１２の周囲から
血管の内！Ｉ！５に向かって次第に血栓が付着して血流
を減少させるものであり、請求項２のようにすると、押
出し成形等により長尺物として製造したものを切断して
塞栓体１を得ることができ、また、請求項３のようにす
ると、塞栓体１１の方向性を無くし、どの方向を向いて
もほぼ同じ効果を得ることができ、さらに、請求項４の
範囲で、注入直後の血流量及びその後の血栓の付着によ
る血流量の減少達磨の調節ができる。(Function) The embolus body 1.11 of the present invention has the following effects due to the flow gap 4.14:
Immediately after embolization, blood flow is ensured, and from around the base 2.12 into the blood vessel! I! According to claim 2, the embolus body 1 can be obtained by cutting a long object manufactured by extrusion molding or the like. Furthermore, according to claim 3, the directionality of the embolus 11 can be eliminated, and almost the same effect can be obtained no matter which direction it faces.Furthermore, within the scope of claim 4, the blood flow and It is possible to control the subsequent decrease in blood flow due to the attachment of thrombi.
（実施例） 本発明の塞栓体の実施例を図面を参照して説明する。(Example) Embodiments of the embolic body of the present invention will be described with reference to the drawings.
第１図及び第２図に示す塞栓体１は、たとえば、直径０
．５鱈程度、長さ１．５ａｍを中心として長さ１厘ない
し２厘程度の円柱状の基部２の側面から高さ０．２ａｍ
程度、幅０．１５Ｍ程度の３つの突部３を基部２の横断
面方向に放射状に突設し、それぞれの突部３の間に流通
間隙４を形成したもので、基部２はそれぞれの突部３に
ついて突設された方向を維持する強度（大きさ）を有し
ている。The embolus body 1 shown in FIGS. 1 and 2 has a diameter of 0, for example.
．． A height of 0.2 am from the side of the cylindrical base 2 with a length of about 1.5 am and a length of about 1 to 2 lin.
Three protrusions 3 with a width of approximately 0.15M are provided radially in the cross-sectional direction of the base 2, and a flow gap 4 is formed between each protrusion 3. It has the strength (size) to maintain the protruding direction of the portion 3.
そして、この塞栓体１は、Ｘ１！不透過とした非融解・
非吸収のシリコンにより永久塞栓物質として一体に形成
され、突部３の突設方向が基部２の横断面方向のため、
押出し成形により長尺物として製造したものを所定の長
さに切断して得ることができる。And this embolus body 1 is X1! Impermeable and non-melting
It is integrally formed with non-absorbable silicone as a permanent embolization material, and the protruding direction of the protrusion 3 is in the cross-sectional direction of the base 2, so
It can be obtained by cutting a long product manufactured by extrusion molding into a predetermined length.
そうして、この塞栓体１を用いてＴＡＥを行なうと、塞
栓体１が血流に乗って流れ、各突部３が血管の内壁５に
当接した位置で血管を閉塞するので、血管の内壁５内の
断面積を、塞栓体１の基部２の中心から突部３の先端ま
での長さ０．４５Ｍ程度を半径とする円の面積と仮定し
て、第１図における塞栓体１の断面投影面積が血管の内
壁５内の断面積の４５％程度となり、３つの流通間隙４
により５５％程度の血流断面積を確保できるので、塞栓
体１を注入した直後の血流をある程度確保でき、この後
、塞栓体１に血栓がｆ％ｔＷすることにより、血流が次
第に減少し、とくに、血栓が塞栓体１の基部２から血管
の内壁５に向かって成長するので、流通間隙４による血
流断面積の減少が急激でなく、血流が完全に無くなるま
での時間を確保することができる。Then, when TAE is performed using this embolus body 1, the embolus body 1 flows along with the blood flow, and the blood vessel is occluded at the position where each protrusion 3 contacts the inner wall 5 of the blood vessel. Assuming that the cross-sectional area within the inner wall 5 is the area of a circle whose radius is approximately 0.45M in length from the center of the base 2 of the embolus 1 to the tip of the protrusion 3, the embolus 1 in FIG. The projected cross-sectional area is approximately 45% of the cross-sectional area within the inner wall 5 of the blood vessel, and there are three circulation gaps 4.
Since it is possible to secure a blood flow cross-sectional area of approximately 55%, a certain amount of blood flow can be secured immediately after the embolus 1 is injected, and after this, the blood flow gradually decreases due to f%tW of thrombi in the embolus 1. However, in particular, since the thrombus grows from the base 2 of the embolus 1 toward the inner wall 5 of the blood vessel, the reduction in the blood flow cross-sectional area due to the flow gap 4 is not rapid, and time is ensured until the blood flow completely disappears. can do.
したがって、この塞栓体１を用い、その注入する塞栓体
１の数を調整して、たとえば、従来の塞栓物質を用いて
注入直後に血流を無くした場合に患者が疼痛を訴える数
日から１週間程度の期間をかけて、血流が無くなるよう
にすると、患者の疼痛が少なくなる。Therefore, by using this embolus 1 and adjusting the number of embolus 1 to be injected, for example, if the patient complains of pain when blood flow is eliminated immediately after injection using a conventional embolization material, the number of embolus 1 to be injected can be adjusted to If blood flow is eliminated over a period of about a week, the patient's pain will decrease.
そして、塞栓体１の断面投影面積を外接する血管の内壁
５内の断面積に比較して小さくすると、誤って、塞栓体
１が目的以外の動脈に注入された場合にも、そのａｌｌ
の１ｆｆｉｉが従来の塞栓物質よりも起りにくい。By making the projected cross-sectional area of the embolic body 1 smaller than the cross-sectional area within the inner wall 5 of the circumscribing blood vessel, even if the embolic body 1 is accidentally injected into an artery other than the intended one, all
1ffii is less likely to occur than conventional embolic materials.
なお、塞栓体１の長さを１．５ｍを中心として１ｍない
し２ｍ程度としたのは、塞栓体１の外接円の直径が０．
９ｍ程度のため、この外接円の直径よりも塞栓体１の長
さを長くしておけば、塞栓体１が所定の方向を向いて、
血管の長さ方向と塞栓体１の長さ方向が一致し易く、所
期の目的つまり血流断面積の確保が期待できることと、
塞栓体１の長さが長ずざると、カテーテルによる塞栓体
１の注入がしにくくなるためである。The reason why the length of the embolus body 1 is set to about 1 m to 2 m with the center being 1.5 m is because the diameter of the circumscribed circle of the embolus body 1 is 0.5 m.
Since it is about 9 m, if the length of the embolus body 1 is made longer than the diameter of this circumscribed circle, the embolus body 1 will face in a predetermined direction.
The length direction of the blood vessel and the length direction of the embolus body 1 are likely to match, and the desired purpose, that is, ensuring the cross-sectional area of blood flow can be expected;
This is because if the length of the embolic body 1 is not long, it becomes difficult to inject the embolic body 1 with a catheter.
また、第３図に示す塞栓体１１は、基部１１から４つの
突部１３をそれぞれの突部１３間の角度を等しくして立
体的に放射状に突設し、それぞれの突部１３の間に流通
間隙１４を形成したテトラポット形状のもので、基部１
２は、それぞれの突部１３を一体的に連結し、それぞれ
の突部１３について突設された方向を維持する強度を有
している。Furthermore, the embolus body 11 shown in FIG. It has a tetrapot shape with a flow gap 14 formed at the base 1.
2 has the strength to integrally connect the respective protrusions 13 and maintain the protruding direction of each protrusion 13.
そして、この塞栓体１１も、第１図及び第２図に示した
塞栓体１と同様に用いることができるが、この塞栓体１
１の場合、４つの突部１３を基部１２から立体的に突設
したので、方向性が無く、どの方向を向いてもほぼ同じ
効果を得ることができる。This embolic body 11 can also be used in the same manner as the embolic body 1 shown in FIGS. 1 and 2, but this embolic body 1
In the case of No. 1, since the four protrusions 13 are provided three-dimensionally to protrude from the base 12, there is no directionality, and almost the same effect can be obtained no matter which direction it faces.
なお、上述した実施例の塞栓体１．１１は、突部３．１
３の数が３つと４つのもので、（れぞれ突部３．１３が
基部２，１２と区分できる略板状あるいは略円柱状であ
るが、基部と突部が明確に区分できない形状、たとえば
、全体として多面体を構成する形状や全体として多角柱
を構成する形状で、それぞれの面を彎曲状に凹陥させた
ものとしてもよく、また、突部の数も５つ以上にするこ
とができるが、流通間隙を多く確保するためには突部の
数をあまり増やさない方がよく、しかも、流通間隙の確
保と血管内での安定性を考えると、第３図のテトラポッ
ト形状の塞栓体１１がよく、この他には、たとえば、３
本の棒をそれぞれ直角に組合わせた形状、すなわち、突
部が６つでそれぞれの突部間の角度が全て直角の形状が
好ましい。In addition, the embolus body 1.11 of the above-mentioned embodiment has the protrusion 3.1.
3 and 4 (the protrusion 3.13 is approximately plate-shaped or approximately cylindrical in shape, which can be distinguished from the bases 2 and 12, respectively, but the base and the protrusion cannot be clearly distinguished, For example, the shape may be a polyhedron as a whole or a polygonal prism as a whole, each face of which may be concave in a curved shape, and the number of protrusions may be five or more. However, in order to ensure a large flow gap, it is better not to increase the number of protrusions too much, and considering the need to secure a flow gap and stability within the blood vessel, the tetrapod-shaped embolus shown in Figure 3 11 is good, but other than this, for example, 3
It is preferable to have a shape in which book sticks are combined at right angles, that is, a shape in which there are six protrusions and all the angles between the protrusions are right angles.
また、塞栓体１，１１の素材は、非融解・非吸収の永久
塞栓物質を構成するシリコンを例示したが、当然のこと
ながら、短期ないし長期の一時的な塞栓物質を構成する
融解性・吸収性の有るもので塞栓体１，１１を形成して
もよく、その必要も求められている。In addition, the material of the embolic bodies 1 and 11 is silicone, which constitutes a non-melting and non-absorbable permanent embolic material, but it goes without saying that silicone, which constitutes a temporary embolic material for a short to long term, is meltable and absorbable. The embolus body 1, 11 may be formed of a material having a certain property, and there is a need for this.
すなわち、悪性腫瘍に対するＴＡＥは、腫瘍の栄養血管
つまり栄養を供給する動脈を閉塞して、腫瘍を壊死させ
ることを目的とするが、永久塞栓物質を用いてＴＡＥを
行なうと、腫瘍の当初の栄ｉ白管が閉塞したままとなる
ので、別の動脈が腫瘍の栄養血管に発達し、ＴＡＥで壊
死せずに残存した腫瘍が新たな栄養血管から栄養を受け
ることになるが、この新たな栄養血管に対するＴＡＥは
、技術的に困難で、不可能なことが多い。In other words, TAE for malignant tumors aims to cause necrosis of the tumor by occluding the tumor's feeding vessels, that is, the arteries that supply nutrition, but when TAE is performed using a permanent embolization material, the initial growth of the tumor is Since the white duct remains occluded, another artery develops as a feeding blood vessel for the tumor, and the remaining tumor that was not necrotized by TAE receives nutrition from the new feeding blood vessel. TAE on blood vessels is technically difficult and often impossible.
そのため、悪性腫瘍に対するＴＡＥには、従来から、−
時的な塞栓物質を用いて、ｒ！１塞した栄養血管を再開
通させることにより、新たな栄養血管が発達しないよう
にし、元からある同じ栄養血管にＴＡＥを繰返して行な
う必要があるためである。Therefore, TAE for malignant tumors has traditionally been
Using temporal embolic agents, r! This is because it is necessary to re-open the occluded feeding blood vessels to prevent the development of new feeding blood vessels, and to repeatedly perform TAE on the same original feeding blood vessels.
なお、塞栓体１，１１の素材として、永久的な塞栓には
、たとえば、シリコン、ポリ塩化ビニル、ポリビニルア
ルコール、テフロン、ポリウレタン、ポリエチレン、ナ
イロン、ポリプロピレン等の合成高分子、または抗血栓
性合成高分子、さらに、貴金属やステンレス等の金属が
考えられ、−時的な塞栓には、たとえば、でんぷん、セ
ルロース、キチン等のポリサッカライドやコラーゲン等
のポリペプチドを生体内分解性に処理したもの、カルシ
ウム塩等の塩類、ｆｉｌｌ（カットガツト）が考えられ
る。For permanent embolization, the materials for the embolus bodies 1 and 11 include synthetic polymers such as silicone, polyvinyl chloride, polyvinyl alcohol, Teflon, polyurethane, polyethylene, nylon, and polypropylene, or antithrombotic synthetic polymers. Molecules, as well as metals such as precious metals and stainless steel, can be considered. - For temporary embolization, for example, polysaccharides such as starch, cellulose, and chitin, polypeptides such as collagen that have been treated to be biodegradable, and calcium. Possible examples include salts such as salt, and fill.
そして、−時的な塞栓体では、その形状が血栓が成長す
るまでの２〜５日間は保たれることが必要であり、また
１〜２週間で融解、吸収されるトｊ′とが悪性腫瘍新た
な栄養血管の発達を防止するｆで望ましい。なお、悪性
腫瘍に対する一時的な塞栓体１．１１の素材には、抗癌
剤を混合してもよい。In the case of a temporary embolus, it is necessary to maintain its shape for 2 to 5 days until the thrombus grows. Preventing the development of new tumor feeding vessels is desirable. Note that an anticancer agent may be mixed into the material of the temporary embolus 1.11 for malignant tumors.
また、血管の内壁５内の断面積を、塞栓体１゜１１の基
部２．１２の中心から突部３，１３の先端までの長さを
半径とする円の面積と仮定し、この円の面積に対する塞
栓体１，１１の投影面積の比率は、３０％〜６０％程度
がよく、これより少ないと、ＴＡＥに用いる塞栓体１，
１１の数を多くしても、塞栓効果が少なく、これより多
いと、ＴＡＥに用いる塞栓体１．１１の数を少なくして
も、１つあたりの塞栓効果が大きく、血流値の調整がむ
ずかしくなる。したがって、望ましくは、４０％〜５０
％程度が適当である。Further, assuming that the cross-sectional area within the inner wall 5 of the blood vessel is the area of a circle whose radius is the length from the center of the base 2.12 of the embolus body 1.11 to the tips of the protrusions 3, 13, The ratio of the projected area of the embolic body 1, 11 to the area is preferably about 30% to 60%, and if it is less than this, the embolic body 1, 11 used for TAE
Even if the number of 11 is increased, the embolic effect is small, and if the number is larger than this, the embolic effect used for TAE is 1. Even if the number of 11 is small, the embolic effect per one is large, making it difficult to adjust the blood flow value. It becomes difficult. Therefore, preferably 40% to 50%
% is appropriate.
（発明の効果）
上述したように、本発明の塞栓体を用いてＴＡＥを行な
うと、基部から突設した突部が血管の内壁に当接した位
置で血管を閉塞するので、それぞれの突部間の流通間隙
によりある程度の自流断面積を確保でき、このため、塞
栓体を注入した直後の血流をある程度確保でき、この後
、塞栓体に血栓が付着することにより、血流が次第に減
少し、とくに、血栓が塞栓体の基部から血管の内壁に向
かって成長するので、流通間隙による自流断面積の減少
が急激でなく、血流が完全に無くなるまでの時間を確保
することができる。(Effects of the Invention) As described above, when TAE is performed using the embolization body of the present invention, the protrusions protruding from the base occlude the blood vessel at the position where they abut against the inner wall of the blood vessel. A certain amount of free flow cross-sectional area can be secured due to the flow gap between the embolus and, therefore, a certain amount of blood flow can be secured immediately after the embolus is injected.After this, blood flow gradually decreases due to thrombus adhering to the embolus. In particular, since the thrombus grows from the base of the embolus toward the inner wall of the blood vessel, the reduction in the cross-sectional area of its own flow due to the flow gap is not rapid, and it is possible to secure time until the blood flow completely disappears.
第１図は本発明の塞栓体の一実施例の正面図、第２図は
その斜視図、第３図は他の実施例の斜視図である。
１．１１・・塞栓体、２．１２・・基部、３．１３・・
突部、４，１４・・流通間隙、５・・血管の内壁。FIG. 1 is a front view of one embodiment of the embolus of the present invention, FIG. 2 is a perspective view thereof, and FIG. 3 is a perspective view of another embodiment. 1.11... Embolic body, 2.12... Base, 3.13...
Projection, 4, 14...Flow gap, 5...Inner wall of blood vessel.
Claims (4)
ぞれの突部の間に流通間隙を形成して成り、上記基部は
それぞれの突部についてその突設された方向を維持する
強度を有することを特徴とする塞栓体。(1) A plurality of protrusions are protruded radially around the base, and a flow gap is formed between each protrusion, and the base maintains the protruding direction of each protrusion. An embolic body characterized by having strength.
されたことを特徴とする請求項１に記載の塞栓体。(2) The embolus according to claim 1, wherein the plurality of protrusions are located on the same plane and protrude from the base.
特徴とする請求項１に記載の塞栓体。(3) The embolus according to claim 1, wherein a plurality of protrusions are provided three-dimensionally protruding from the base.
の長さを半径とする円の面積の３０％〜６０％であるこ
とを特徴とする請求項１ないし３のいずれかに記載の塞
栓体。(4) The entire projected area is 30% to 60% of the area of a circle whose radius is the length from the center of the base to the tip of the protrusion. Embolized body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63175549A JPH0223952A (en) | 1988-07-14 | 1988-07-14 | Thrombolic body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63175549A JPH0223952A (en) | 1988-07-14 | 1988-07-14 | Thrombolic body |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0223952A true JPH0223952A (en) | 1990-01-26 |
| JPH0554981B2 JPH0554981B2 (en) | 1993-08-13 |
Family
ID=15998023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63175549A Granted JPH0223952A (en) | 1988-07-14 | 1988-07-14 | Thrombolic body |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0223952A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5168992A (en) * | 1974-11-04 | 1976-06-15 | Gambro Ag |
-
1988
- 1988-07-14 JP JP63175549A patent/JPH0223952A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5168992A (en) * | 1974-11-04 | 1976-06-15 | Gambro Ag |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0554981B2 (en) | 1993-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1100541B1 (en) | Hydrogel for the therapeutic treatment of aneurysms | |
| US4795741A (en) | Compositions for therapeutic percutaneous embolization and the use thereof | |
| US5894022A (en) | Embolic material for endovascular occlusion of abnormal vasculature and method of using the same | |
| Makuuchi et al. | Bile duct necrosis: complication of transcatheter hepatic arterial embolization. | |
| Vaidya et al. | An overview of embolic agents | |
| US4268495A (en) | Injectable embolization and occlusion solution | |
| JP4860876B2 (en) | Biocompatible material composition adaptable to various therapeutic indications | |
| Berenstein et al. | Gelatin sponge in therapeutic neuroradiology: a subject review. | |
| US20040091543A1 (en) | Embolic compositions | |
| JP2003535658A (en) | System and method for sealing a vascular penetration using a hemostatic gel | |
| US20220039801A1 (en) | Systems and methods for delivery of gel embolics | |
| JP2009082728A (en) | Composition, system and method for treatment of defects in blood vessel | |
| Horák et al. | Hydrogels in endovascular embolization. II. Clinical use of spherical particles | |
| Greenfield | Transcatheter vessel occlusion: selection of methods and materials | |
| JPH0223952A (en) | Thrombolic body | |
| Cromwell et al. | Histologic analysis of tissue response to bucrylate-pantopaque mixture | |
| JP3530200B2 (en) | Vascular embolic agent | |
| Paster et al. | Percutaneous catheter-aided infarction of renal tumors: a preliminary report | |
| Phillips et al. | Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. | |
| Kish et al. | Histopathologic effects of transarterial bucrylate occlusion of intracerebral arteries in mongrel dogs. | |
| Horák et al. | Use of poly (2-hydroxyethyl methacrylate) for endovascular occlusion in pediatric surgery | |
| CN115475245A (en) | Use of MEK inhibitors for the preparation of a product for the treatment of arteriovenous malformations | |
| JPH0420348A (en) | Blood vessel restoring material and method for using this material | |
| Senaldi et al. | Mortality and platelet depletion occur independently of fibrinogen consumption in murine models of tumour necrosis factor-mediated systemic inflammatory responses | |
| RU2627855C1 (en) | Hemostatic sponge (versions) |